FLUO Relative Valuation - Fluoguide AS - Alpha Spread
F

Fluoguide AS
STO:FLUO

Watchlist Manager
Fluoguide AS
STO:FLUO
Watchlist
Price: 40.4 SEK -0.62%
Market Cap: 550.3m SEK
Have any thoughts about
Fluoguide AS?
Write Note

Relative Value

There is not enough data to reliably calculate the relative value of FLUO.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FLUO Relative Value
Base Case
Not Available
F
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.7
vs History
vs Industry
Median 3Y
-18.4
Median 5Y
-28.9
Industry
23.9
Forward
-6.5
vs History
vs Industry
Median 3Y
-19.5
Median 5Y
-29.1
Industry
22.2
vs History
vs Industry
Median 3Y
-19.7
Median 5Y
-28.9
Industry
24
vs History
79
vs Industry
1
Median 3Y
16.9
Median 5Y
18.2
Industry
2.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.5
vs History
vs Industry
Median 3Y
-14.5
Median 5Y
-21.3
Industry
5.1
Forward
-5
vs History
vs Industry
Median 3Y
-14.4
Median 5Y
-23.8
Industry
4.7
Forward
-5
vs History
vs Industry
Median 3Y
-17.3
Median 5Y
-27.1
Industry
6.6
vs History
vs Industry
Median 3Y
-17.3
Median 5Y
-27.1
Industry
4.7
vs History
77
vs Industry
7
Median 3Y
64.2
Median 5Y
79
Industry
4.7

Multiples Across Competitors

FLUO Competitors Multiples
Fluoguide AS Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Fluoguide AS
STO:FLUO
504.5m SEK 0 -9.1 -7.6 -7.6
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
127.8B USD 9.5 29.6 25.9 28.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.3B USD 11.9 -251.7 26.8 28.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.7 22.4 27.9
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
DK
F
Fluoguide AS
STO:FLUO
Average P/E: 57.5
Negative Multiple: -9.1
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.6
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -251.7
38%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A
EV/EBITDA Multiple
EBITDA Growth
DK
F
Fluoguide AS
STO:FLUO
Average EV/EBITDA: 47.7
Negative Multiple: -7.6
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.9
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
213.7
N/A
EV/EBIT Multiple
EBIT Growth
DK
F
Fluoguide AS
STO:FLUO
Average EV/EBIT: 69.5
Negative Multiple: -7.6
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
28.7
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
38%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
AU
CSL Ltd
ASX:CSL
27.9
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
328.9
N/A

See Also

Discover More
Back to Top